ARISTOCORT
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Mar 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ARISTOCORT is an injectable small-molecule corticosteroid approved in 1959 for inflammatory and autoimmune conditions. The drug is administered via injection and works by suppressing immune and inflammatory responses. Specific indications are not detailed in available data.
LOE Approaching
As an aging branded injectable approaching loss of exclusivity, the commercial team is likely focused on retention and cost management rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ARISTOCORT offers limited career growth potential given its mature, LOE-approaching status and zero linked job openings. Roles on this product are primarily focused on defending market share and managing the transition to generic competition rather than building new capabilities.
Brand ManagerField Sales Representative
Worked on ARISTOCORT at Fosun Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.